{'fraction_non_alphanumeric': 0.03901170351105332, 'fraction_numerical': 0.009102730819245773, 'mean_word_length': 5.260162601626016, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 1, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
The right treatment for the right patient with COPD: lessons from the IMPACT trial

Long-acting bronchodilators are the basis of treatment for COPD [1]; however, there are some patients who suffer from frequent or severe exacerbations, despite maximal bronchodilation [2]. These patients are at increased risk of death and represent a great challenge in clinical practice [3]. Inhaled corticosteroids (ICS) are the basis of the treatment of asthma and are also effective, albeit to a lesser extent, in some patients with COPD [4]. Generally speaking, ICS are indicated in patients with COPD and exacerbations, despite bronchodilator treatment [1]. Different patient characteristics have to be considered for prescription of triple therapy in COPD https://bit.ly/2xWq7lW